PubMed Triage Digest — 2026-08-04

Run ID: 2026-08-04-attempt2-20260804T091821Z | Pipeline v1.3 | Status: SUCCESS
Search window: 2026-08-03 → 2026-08-04 | Topics: 9 watchlist + sentinel

🔴 EXPEDITE (triage_score 9) — 6 articles

1. O-GlcNAc Transferase as Oncogenic Regulator Across Hematologic Malignancies

PMID: 42546407 | Score: 9/10 | Biomed Pharmacother | 2026-08-03
Topic: hematologic_malignancies
DOI: 10.1016/j.biopha.2026.119822
Authors: El Hajje M, Coelho-Silva JL, Machado-Neto JA, Trossini GHG
Study design: Systematic review | Evidence: Review
Finding: OGT exhibits the highest expression in hematologic malignancies among all cancer lineages, acting via four axes: PD-L1 immune evasion, phosphoproteome crosstalk, MYC/p53/STAT5 stabilization, and EZH2/TET epigenetic reprogramming; ASXL1 mutation status is the leading stratification biomarker for OGT-targeting therapy.
Why it matters: Mechanistic framework unifying OGT across AML, CLL, DLBCL, MCL, and myeloma with defined drug stratification biomarkers (ASXL1/p53); OSMI-series inhibitors and TPR-directed polypeptides identified as lead therapeutic strategies. Disease-highest OGT expression establishes a unique metabolic-epigenetic oncobiological axis warranting dedicated drug discovery effort.

2. Oncofetal Chondroitin Sulfate on Tumor-Derived EVs: Novel Pan-Cancer Liquid Biopsy Target

PMID: 42546853 | Score: 9/10 | Biochim Biophys Acta Rev Cancer | 2026-08-03
Topic: early_cancer_detection
DOI: 10.1016/j.bbcan.2026.189674
Authors: Boerrigter EPEM, Ten Dijke P, Nieuwland R, Enciso-Martinez A
Study design: Narrative review | Evidence: Emerging
Finding: ofCS, a placenta-restricted glycosaminoglycan re-expressed on tumor-derived extracellular vesicles across diverse cancers, is detectable in pancreatic cancer patient plasma, offering a pan-cancer cancer-restricted surface handle for next-generation tdEV-based liquid biopsy.
Why it matters: Addresses the fundamental unmet need in tdEV liquid biopsy—lack of robust pan-cancer cancer-specific surface markers. Patient plasma validation in pancreatic cancer (where early detection is critically needed) provides immediate translational pathway. Informs liquid biopsy platform development strategy.

3. AI-Based Model Identifies Actionable PTPRZ1-MET Fusion in Secondary Glioblastoma

PMID: 42547688 | Score: 9/10 | Mol Biomed (Open Access) | 2026-08-04
Topic: ai_clinical_diagnostics | Sentinel cross-hit
DOI: 10.1186/s43556-026-00529-x
Authors: Zhang JH, Shi J, Zhou HX, Tan WL, Zhang Y, Jiang T, Zhao Z
Study design: Diagnostic model development | Evidence: Emerging
Finding: AI diagnostic model accurately identifies PTPRZ1-MET fusion in a clinically defined secondary GBM cohort, enabling non-invasive stratification of this actionable molecular subtype associated with rapid progression and temozolomide resistance.
Why it matters: PTPRZ1-MET defines a molecularly distinct secondary GBM subset with MET inhibitor–targetable kinase activity but historically requiring tissue biopsy for identification; non-invasive AI stratification addresses a critical diagnostic gap for this aggressive orphan indication.

4. Agonistic Anti-OX40 Nanobody Platform via Epitope-Directed Discovery

PMID: 42547263 | Score: 9/10 | J Immunother Cancer (Open Access) | 2026-08-03
Topic: precision_oncology_genomics
DOI: 10.1136/jitc-2025-014419
Authors: Iemura T, Kitawaki T, Maeda R, et al. (11 authors)
Study design: Experimental preclinical | Evidence: Early
Finding: Epitope-directed screening identified Nb479, a potent gp34-mimicking OX40 agonist nanobody; trimeric Nb479 conjugated with anti-serum albumin nanobody shows improved PK and enhanced anti-tumor activity in combination with CD19 CAR-T cells in vivo.
Why it matters: OX40 co-stimulation has been a high-priority but clinically intractable immunotherapy target; this is the first potent agonist nanobody with validated in vivo efficacy. The epitope-directed discovery platform addresses the biases that have prevented prior OX40 antibody discovery successes. Patent filed; direct translational pathway.

5. Bispecific ANXA2/CD147 CAR-T for Osteosarcoma Overcomes Antigen Escape

PMID: 42547556 | Score: 9/10 | Oncogene | 2026-08-03
Topic: novel_therapeutics_immunotherapy
DOI: 10.1038/s41388-026-03926-2
Authors: Tang HJ, Dai W, Xiao DT, Li HN, et al. (16 authors)
Study design: Experimental preclinical | Evidence: Early
Finding: Bispecific ANXA2/CD147-targeting CAR-T cells demonstrate preclinical efficacy against osteosarcoma; dual-antigen targeting mitigates antigen-loss escape, the primary CAR-T resistance mechanism in solid tumors.
Why it matters: Osteosarcoma is a pediatric rare cancer with critical unmet need at relapse and very limited approved targeted options; the dual-antigen bispecific approach addresses the fundamental solid tumor CAR-T barrier; Oncogene publication ensures rigorous peer review.

6. Landscape of Genetic Medicines for In Vivo T Cell Reprogramming

PMID: 42546776 | Score: 9/10 | Adv Drug Deliv Rev | 2026-08-03
Topic: novel_therapeutics_immunotherapy
DOI: 10.1016/j.addr.2026.115940
Authors: Simonsen JB, Lemgart VT, Kulkarni JA, Witzigmann D
Study design: Narrative review | Evidence: Emerging
Finding: Comprehensive landscape of in vivo T cell reprogramming platforms (LNPs, AAV, lentiviral vectors) delivering CAR genetic cargo directly in patients; LNP-based mRNA delivery is closest to clinical readiness; key bottlenecks in T-cell selectivity and payload persistence identified.
Why it matters: In vivo CAR-T represents the next-wave cell therapy paradigm bypassing costly ex vivo manufacturing; could democratize access to cell therapy. Published by leading drug delivery scientists in the top drug delivery review journal; maps investment and partnership priorities for next-generation immunotherapy pipeline.

🟠 HIGH (triage_score 8) — 2 articles

7. Sysmex XN-3100 SCHISTO-DI Achieves 100% Sensitivity for Early TMA Detection

PMID: 42547087 | Score: 8/10 | Int J Lab Hematol | 2026-08-03
Topic: early_cancer_detection | CBC/ML cross-hit
DOI: 10.1111/ijlh.70208
Authors: Milos M, Matkovic L, Kuvezdic KG, Ries S, Medic M, Pulanic D, Herak DC
Study design: Diagnostic validation | Evidence: Emerging
Finding: XN-3100 digital morphology SCHISTO-DI matches light microscopy gold standard with 100% sensitivity/NPV for TMA in 91 samples from 54 patients; standard FRC channel fails with 66.7% sensitivity and five false negatives.
Why it matters: Directly actionable: SCHISTO-DI should replace FRC-based schistocyte counting in clinical laboratories for early TMA/HUS detection; TMA diagnosis is a life-threatening emergency requiring speed; validated automated solution eliminates the bottleneck of microscopy-dependent gold standard.

8. ctDNA Surveillance Detects Breast Cancer Recurrence 6 Months Before Imaging

PMID: 42545412 | Score: 8/10 | Ann Surg Oncol | 2026-08-03
Topic: precision_oncology_genomics
DOI: 10.1245/s10434-026-20252-9
Authors: Taylor N, Chew YL, Ng TS, Palesty JA, Sieling B, Sookhan N
Study design: Retrospective cohort (n=227) | Evidence: Emerging
Finding: 4.41% ctDNA positivity in stage I-III breast cancer serial Signatera testing; all ctDNA+ underwent PET (70% confirmed metastases); ctDNA preceded imaging confirmation by 6 months in one patient.
Why it matters: Real-world clinical validation of commercial Signatera ctDNA demonstrating a 6-month imaging lead time for recurrence detection; directly actionable for high-risk breast cancer surveillance protocol design and liquid biopsy clinical integration.

🟡 STANDARD (triage_score 5–7) — Selected highlights by topic

Hematologic Malignancies

• 42547582 (7/10) — Copper dependency in leukemia metabolism, Nat Cancer perspective from St. Jude; emerging therapeutic paradigm for AML copper-targeting
• 42546996 (7/10) — Cryo-EM DNMT3A-TCL1A complex, J Struct Biol; allosteric inhibition mechanism for TCL1A-driven epigenetics in CLL/AML
• 42546663 (6/10) — Geriatric oncology equity in elderly leukemia patients; health equity focus in hematologic malignancies

Early Cancer Detection

• 42547281 (7/10) — Navigating pulmonary nodules for primary care, Cleve Clin J Med; Fleischner/LUNG-RADS guideline synthesis for early lung cancer
• 42547718 (7/10) — FBLIM1 biomarker for early HNSCC; novel cancer biomarker for poor-prognosis head/neck cancer

AI/ML in Diagnostics

• 42547590 (7/10) — AI systematic review in breast cancer imaging; validation evidence synthesis
• 42547423 (7/10) — AI for cervical cytology screening; high-impact population screening application
• 42545470 (7/10) — AI meta-analysis in urological cancer radiology; pooled comparative performance
• 42546187 (7/10) — Deep learning brain aging mapping from standard MRI, PNAS; cross-hit aging/AI diagnostics

Precision Oncology

• 42546665 (7/10) — Unified DNA/RNA amplicon NGS for NSCLC fusion detection; single-workflow molecular profiling

Novel Therapeutics

• 42547554 (7/10) — TRPA1+ CAF Treg circuit drives immunotherapy resistance in gastric cancer, Oncogene; novel resistance mechanism target
• 42546925 (7/10) — Anti-PD-1 + irreversible electroporation for HCC; IRE as immunotherapy sensitizer
• 42547098 (7/10) — CAR-T pharmacology review for autoimmune disease; expanding CAR-T beyond oncology

Cardiovascular-Metabolic

• 42547586 (7/10) — HF incidence in 19,892 newly diagnosed diabetes patients, Diabetologia; large population cardiometabolic risk data
• 42547763 (7/10) — External validation of SELECT trial CV risk equations; semaglutide CVD indication data
• 42547732 (7/10) — DOACs in AF network meta-analysis; comparative cardiac outcome effectiveness
• 42547656 (7/10) — Peripheral nerve complications from weight loss medications, J Neurol; GLP-1 adverse effect systematic review
• 42547165 (7/10) — MagMa Study: quantum magnetocardiography in cardiomyopathy, JACC Heart Fail; emerging diagnostic technology

Aging & Longevity

• 42545930 (6/10) — LysoTracker lysosomal profiling for cellular senescence quantification, JoVE; methods advancement for aging research

Rare Diseases

• 42547698 (7/10) — Neural stem cells in MS: preclinical and clinical evidence, comprehensive review
• 42546826 (7/10) — Unmet need in fibrous dysplasia and rare paediatric bone disease, Bone; GNAS-targeted therapy rationale
• 42545825 (7/10) — STAT5B mutation: severe atopic dermatitis + growth failure in infant; rare immunodeficiency phenotypic expansion
• 42545582 (7/10) — FLVCR1-associated ocular and genetic spectrum expansion in Chinese cohort; hereditary retinal disease
• 42545441 (7/10) — WDR72-associated distal RTA with renal cysts; ultra-rare disease phenotypic expansion

📊 Coverage Summary

Total articles in output array: 30 (8 EXPEDITE/HIGH with abstracts; 22 STANDARD with conservative title-only caps)
Classification confidence: HIGH (abstract-confirmed): 15 | MEDIUM (esummary-confirmed): 9 | LOW (title-only): 6

Generated by PubMed Triage Pipeline v1.3 | Run: 2026-08-04-attempt2-20260804T091821Z